Iovance Biotherapeutics Inc

NASDAQ:IOVA 1:00:00 PM EDT

1.75

0.00 (0.00%)

4:57:58 PM EDT: $1.75 0.00 (0.01%)

Market Cap (Intraday)	584.39M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$67.1 Million
Adjusted EPS	-$0.28

See more estimates

10-Day MA	$1.79
50-Day MA	$2.21
200-Day MA	$5.82

See more pivots

Iovance Biotherapeutics Inc Stock, NASDAQ:IOVA

825 Industrial Road, Suite 400, San Carlos, California 94070

United States of America

Phone: +1.650.260.7120

Number of Employees: 838

http://www.iovance.com

Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.